Previous 10 | Next 10 |
2024-04-15 16:08:10 ET Summary Given the huge and growing GLP-1 weight loss market, recent trial data from Viking Therapeutics could make it a potential acquisition target for a larger concern. While many bigger pharma names might desire entry into the huge GLP-1 weight loss marke...
2024-04-12 12:02:31 ET Summary Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight lo...
2024-03-31 10:47:12 ET Summary Eli Lilly's stock has surged in the first quarter of 2024 due to the success of its weight loss products in the pharma market. A huge rally has powered the shares to a gain of 130% over the past 12 months and the stock to a $700 billion market cap. ...
2024-03-27 19:50:00 ET Summary Positive results achieved from phase 2 MOMENTUM study, whereby patients not only achieved significant weight loss over a 48-week period with pemvidutide but also had lean mass preservation. It is said that the GLP-1 market could exceed $100 billion b...
2024-03-27 12:35:06 ET Altimmune, Inc. (ALT) Q4 2023 Results Conference Call March 27, 2024 8:30 AM ET Company Participants Scott Harris - CMO Vipin Garg - CEO Rich Eisenstadt - CFO Scot Roberts - CSO Conference Call Participants Corinne Jenkins -...
2024-03-27 08:26:15 ET More on Altimmune Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune Q4 202...
2024-03-27 07:02:15 ET More on Altimmune Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune stock ...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinic...
2024-03-26 13:52:20 ET More on Altimmune Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune stock ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...